(MENAFN- Navistrat Analytics) October 14, 2025- Rising demand for mRNA-based therapeutics is a key driver of revenue growth in the in vitro transcription template market. The therapeutic use of messenger RNA (mRNA) has raised high hopes for combating a wide spectrum of incurable disorders. Furthermore, in vitro transcribed mRNA has achieved planned production, which is more effective, faster to design and produce, adaptable, and cost-efficient than traditional procedures. Unlike DNA-based medications, mRNA transcripts have a relatively high transfection efficiency and low toxicity since they do not require entry into the nucleus to act.

On November 2024, Synthego has expanded its solution portfolio with the addition of high-performance RNA enzymes, T7 RNA Polymerase and RNase Inhibitor, bolstering its ability to service the RNA research and therapeutic sectors. These recently released in vitro transcription (IVT) enzymes are specifically intended to address important issues in RNA synthesis and modification, and they supplement Synthego's industry-leading gRNAs.

Despite its many benefits, in vitro transcription (IVT) faces several challenges, including issues related to enzyme specificity and efficiency, high production costs, process optimization, and the stability and shelf life of synthesized mRNA. The limited stability and short shelf life of mRNA remain major hurdles in the development, formulation, storage, and transportation of mRNA-based therapeutics.

Segments market overview and growth Insights
Based on the product type, the in vitro transcription template market is segmented into enzymes, kits and reagents, and custom synthesis. Enzymes segment contributed the largest share in 2024. In vitro transcription enzymes are pivotal in enabling the controlled enzymatic production of RNA molecules from DNA templates in laboratory environments. Unlike biological transcription, IVT allows researchers full control over RNA sequence, length, and modifications. In January 2025, Aldevron, a global leader in DNA, RNA, and protein manufacturing, introduced Alchemy cell-free DNA technology, a major innovation in synthetic DNA production. This cell-free enzymatic process facilitates the creation of linear DNA (linDNA) templates, marking a significant leap in template synthesis efficiency and scalability.

Regional market overview and growth insights
North America held the largest market share in the In Vitro Transcription Template market in 2024. The market’s growth is further supported by the rising prevalence of chronic diseases. For instance, according to the American Lung Association, cystic fibrosis affects around 40,000 people in the U.S. and 100,000 globally, with approximately 1 in 30 Americans being carriers.

Competitive Landscape and Key Competitors
The In Vitro Transcription Template market is characterized by a fragmented structure, with many competitors holding a significant share of the market. List of major players included in the In Vitro Transcription Template market report are:

o Takara Bio Inc
o Bio-Synthesis Inc
o Integrated DNA Technologies, Inc.
o TriLink BioTechnologies
o Promega Corporation
o GenScript Biotech Corporation
o New England Biolabs
o Amsbio
o Thermo Fisher Scientific Inc.
o Synthego Holdings LLC
o OZ Biosciences
o GeneCopoeia, Inc.
o Creative Biolabs
o GeneBio Systems
o F. Hoffmann-La Roche Ltd

Major strategic developments by leading competitors
TriLink BioTechnologies: In May 2025, TriLink BioTechnologies, a Maravai LifeSciences company, announced a major contribution to academic laboratories in the U.S. and Europe, coinciding with the launch of its first mRNA synthesis kit featuring CleanCap capping technology. This all-in-one kit simplifies the mRNA synthesis workflow by integrating advanced reagents into a single, cost-effective package, underscoring ongoing innovation in the IVT field.

Eurofins Genomics Blue Heron: In June 2023, Eurofins Genomics Blue Heron introduced its advanced IVT mRNA Synthesis Services, offering researchers a comprehensive solution for custom, high-quality mRNA production with fast turnaround times. The service leverages state-of-the-art in vitro transcription (IVT) technology to enable the rapid and efficient generation of high-purity messenger RNA transcripts, meeting the growing demand for precision and reliability in mRNA research and development.

Navistrat Analytics has segmented the In Vitro Transcription Template market based on product type, application, indication, end-use, and region:
• Product Type Outlook (Revenue, USD Million; 2022-2032)
o Enzymes
o Kits and Reagents
o Custom Synthesis

• Application Outlook (Revenue, USD Million; 2022-2032)
o mRNA Therapeutics and Vaccines
o Gene Therapy and Cell Therapy
o RNA Research & Functional Studies
o Personalized Medicine & Oncology
o Diagnostics
o Others

• Indication Outlook (Revenue, USD Million; 2022-2032)
o Cancer
o Infectious Disease
o Lifestyle Disease
o Genetic Disease
o Neurological Disorders
o Others

• End-Use Outlook (Revenue, USD Million; 2022-2032)
o Pharmaceutical & Biotechnology Companies
o Academic & Research Institutions
o Contract Research Organizations (CROs)
o Others

• Regional Outlook (Revenue, USD Million; 2022-2032)
o North America
a. U.S.
b. Canada
c. Mexico

o Europe
a. Germany
b. France
c. U.K.
d. Italy
e. Spain
f. Benelux
g. Nordic Countries
h. Rest of Europe

o Asia Pacific
a. China
b. India
c. Japan
d. South Korea
e. Oceania
f. ASEAN Countries
g. Rest of APAC

o Latin America
a. Brazil
b. Rest of LATAM

o Middle East & Africa
a. GCC Countries
b. South Africa
c. Israel
d. Turkey
e. Rest of MEA

@Navistrat Analytics

MENAFN15102025008152017457ID1110198553